drugset
drugset / Trial / NCT04336904

Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19

NCT04336904 ↗

Phase 3 Unknown 100 enrolled Giuliano Rizzardini
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates treatment with Favipiravir combined with supportive care for adult patients with COVID-19-moderate type.

Timeline

Start
2020-03-25
Primary completion
2020-07
Completion
2020-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Favipiravir Small molecule 600 mg —

Indications

COVID-19